StockNews.AI
ADAG
StockNews.AI
202 days

CD47 Inhibitor Drug Clinical Trials Market Opportunity Outlook 2028, Competitive Analysis of Adagene, ALX, ImmuneOncia, ImmuneOnco, Light Chain Bioscience, Phanes, and Virtuoso,

1. CD47 inhibitors show significant development potential in cancer immunotherapy. 2. Market growth is driven by rising cancer incidence and commercial interest. 3. Combining CD47 inhibitors with existing treatments is a key strategy. 4. Gilead's and Pfizer's acquisitions indicate strong market competition. 5. No CD47 inhibitor is currently approved, highlighting ongoing research.

8m saved
Insight
Article

FAQ

Why Bullish?

Strong market interest and ongoing CD47 clinical trials can positively influence ADAG's prospects.

How important is it?

The article indicates significant trends in CD47 therapies impacting companies like ADAG in the future.

Why Long Term?

As CD47 inhibitors progress through trials, ADAG may benefit from increased market presence over time.

Related Companies

ADAGGILDPFE
Dublin, Jan. 29, 2025 (GLOBE NEWSWIRE) -- The "Global CD47 Inhibitor Drug Clinical Trials Insight & Market Opportunity Outlook 2028" report has been added to ResearchAndMarkets.com's offering. The market for CD47 inhibitors has both opportunities and challenges. Strong commercial interest and encouraging clinical evidence point to substantial development potential. However, there are challenges to address, such managing toxicity profiles, coming up with the best combination plans, and demonstrating distinct therapeutic advantages over current treatments. As the field develops, biomarker development for response prediction and patient selection will probably become more crucial for clinical development as well as marketing tactics.Global CD47 Inhibitor Drug Clinical Trials Insight & Market Opportunity Outlook 2028 Report Highlights Global & Regional Market Opportunity OutlookInsight On More Than 100 CD47 Inhibitor Drugs In Clinical TrialsGlobal CD47 Inhibitors Clinical Trials Insight By Company, Country, Indication & PhaseOrphan, Fast Track, Breakthrough Therapy Designation InsightKey Drugs Initiation & Completion YearCD47 Clinical Application & Development Outlook By IndicationCD47 Inhibitor Drugs Clinical Developments & Trends By CountryGlobal CD47 Inhibitor Drug Market Dynamics Inhibition of the cell surface protein CD47 has emerged as a novel cancer immunotherapy approach that has piqued the interest of both academia and industry in the recent years. Cancer cells often overexpress CD47, which triggers the "don't eat me" signal pathway, thereby helping malignant cells to escape immune surveillance. CD47 inhibitors seek to uncover cancer cells by inhibiting this protein, leaving them open to immune system attack, specifically through increased macrophage phagocytosis. Although no CD47 inhibitor is currently approved for therapeutic usage, the availability of candidates in phase 3 trials suggests that one may be approved in the coming years. With multiple candidates at varying stages of development, the field of CD47 inhibitor research and development is rapidly evolving. Developed by Forty Seven, which is now a part of Gilead, magrolimab is among the most advanced CD47 inhibitors. In early stage clinical trials for hematological tumors, it has demonstrated encouraging outcomes, especially when combined with other cancer treatments. Furthermore, late stage clinical trials evaluating Magrolimab in solid cancer alongside conventional cancer treatments such as docetaxel, Nivolumab, Pembrolizumab, Azacitidine, and Venetoclax are now under progress. Another significant candidate is Evorpacept (ALX148) from ALX Oncology, a high affinity SIRP? fusion protein that inhibits CD47. Currently, evorpacept is being assessed as a monotherapy and in combination with widely used anticancer drugs in a number of early phase clinical trials for a variety of solid and hematological tumors. Furthermore, a late-phase trial evaluating Evorpacept in combination with Trastuzumab, Ramucirumab, and Paclitaxel for the treatment of HER2+ gastric cancer is also under progress. A number of other CD47 inhibitors, including as TQB 2928 (Chia Tai Tianqing Pharmaceutical), MP 0621 (Molecular Partners), IMC-002 (ImmuneOncia Therapeutics), and CC 90002 (Celgene), are in the early phases of clinical research. The emphasis on combination therapies is undoubtedly one of the key trends in clinical development. Combining CD47 inhibitors with other immunotherapies, targeted treatments, and chemotherapy is being studied in an effort to overcome resistance mechanisms and provide synergistic benefits. Anticipated growth in the global market for CD47 inhibitors is attributed to the rising cancer incidence and increased use of immunotherapies in the upcoming years. The potential of CD47 inhibitors has been acknowledged by a number of prominent pharmaceutical companies, which has resulted in notable partnerships and acquisitions. The commercial interest in this field is demonstrated by Gilead Science's US$ 4.9 billion acquisition of Forty Seven in 2020 and Pfizer's US$ 2.26 billion acquisition of Trillium Therapeutics in 2021. Although Chinese and American companies presently dominate the market, there is increasing participation from South Korea, Australia, Canada, and Japan. Through clinical research, companies such as Shaperon, InnobationBio, Bitterroot Bio, and ImmuneOncia Therapeutics are making strides with their CD47 inhibitors. The market is becoming increasingly competitive, with several firms striving for market share. Therefore, for commercial success, differentiation based on safety profile, efficacy, and possible combination strategies will be essential. In conclusion, the market for CD47 inhibitors globally is an active rapidly expanding area of cancer immunotherapy. In the years to come, CD47 inhibitors could have a big impact on cancer therapy paradigms because there are several candidates in clinical development and a lot of commercial interest. Key Topics Covered: 1. CD 47 As Novel Cancer Immunotherapy Target 2. Global CD47 Inhibitors Drug Clinical Pipeline Overview2.1 By Country2.2 By Company2.3 By Indication2.4 By Patient Segment2.5 By Phase2.6 By Priority Status 3. CD47 Inhibitors Clinical Trials Insight By Company, Country, Indication & Phase3.1 Research3.2 Preclinical3.3 Phase I3.4 Phase I/II3.5 Phase II3.6 Phase II/III3.7 Phase III 4. Global CD47 Inhibitor Drug Market Opportunity Outlook4.1 Current Market Overview4.2 Future Outlook & Opportunities 5. CD47 Clinical Application & Development Outlook by Indication5.1 Solid Cancers5.1.1 Breast Cancer5.1.2 Colorectal Cancer5.1.3 Lung Cancer5.1.4 Urogenital Cancer5.1.5 Gastrointestinal Cancer5.2 Hematological Malignancies5.2.1 Lymphoma5.2.2 Leukemia5.2.3 Multiple Myeloma5.2.4 Myelodysplastic Syndrome5.3 Microbial Infections 6. CD47 Inhibitor Drugs Clinical Developments & Trends By Country6.1 China6.2 US6.3 South Korea6.4 Australia6.5 Canada 7. Global CD47 Inhibitors Market Dynamics7.1 Favorable Parameters7.2 Market Restraints 8. Competitive Landscape8.1 Adagene8.2 ALX Oncology8.3 ImmuneOncia Therapeutics8.4 ImmuneOnco Biopharma8.5 Light Chain Bioscience8.6 Phanes Therapeutics8.7 Virtuoso Therapeutics For more information about this report visit https://www.researchandmarkets.com/r/1c8ppz About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Related News